Abstract:Plasmodium falciparum malaria, which degrades haemoglobin through falcipain-2 (FP2), is a serious disease killing 445 thousand people annually. Since the P. falciparum's survival in humans depends on its ability to degrade human's haemoglobin, stoppage or hindrance of FP2 has antimalarial effects. Therefore, we studied the atomic details of how E64 approaches, binds to, and inhibits FP2. We found that E64 (1) gradually approaches FP2 by first interacting with FP2's D170 and Q171 or N81, N77, and K76; (2) binds FP2 tightly (ΔGbinding = -12.2 ± 1.1 kJ/mol); and (3) persistently blocks access to FP2's catalytic residues regardless of whether or not E64 has already been able to form a covalent bond with FP2's C42. Furthermore, the results suggest that S41, D234, D170, N38, N173, and L172 (which are located in or near the FP2's catalytic site's binding pocket) contribute the most towards the favourable binding of E64 to FP2. Their in silico mutations adversely affect E64-FP2 binding affinity with D234L/A, N173L/A, W43F/A, D234L/A, H174F/A, and N38L/A having the most significant adverse effects on E64-FP2 binding and interactions. The findings presented in this article, which has antimalarial implications, suggest that hydrogen bonding and electrostatic interactions play important roles in E64-FP2 binding, and that a potential FP2-blocking E64-based/E64-like antimalarial drug should be capable of being both hydrogen-bond donor and acceptor, and/or have the ability to favourably interact with polar amino acids (such as S41, S149, N38, N173, N77, Q171) and with charged amino acids (such as D234, D170, H174) of FP2. The abilities to favourably interact with ASN, ASP, and SER appears to be important characteristics that such potential drug should have.

Inhibition of falcilysin from Plasmodium falciparum by interference with its closed-to-open dynamic transition

The complex of Plasmodium falciparum falcipain-2 protease with an (E)-chalcone-based inhibitor highlights a novel, small, molecule-binding site

In silico investigation of falcipain-2 inhibition by hybrid benzimidazole-thiosemicarbazone antiplasmodial agents: A molecular docking, molecular dynamics simulation, and kinetics study

BDA-410: a novel synthetic calpain inhibitor active against blood stage malaria.

Dietary Flavonoids Fisetin and Myricetin: Dual Inhibitors of Plasmodium Falciparum Falcipain-2 and Plasmepsin II.

Structural characterization of the Plasmodium falciparum lactate transporter PfFNT alone and in complex with antimalarial compound MMV007839 reveals its inhibition mechanism

Structure-Function of Falcipains: Malarial Cysteine Proteases

Inhibition of Plasmodium falciparum Lysyl-tRNA synthetase via an anaplastic lymphoma kinase inhibitor

Design and Synthesis of Small Molecular Dual Inhibitor of Falcipain-2 and Dihydrofolate Reductase As Antimalarial Agent

Targeting Pf CLK3 with Covalent Inhibitors: A Novel Strategy for Malaria Treatment

Inhibiting the activity of malarial drug target Plasmepsin V by quinolines in aqueous medium

Targeting PfCLK3 with Covalent Inhibitors: A Novel Strategy for Malaria Treatment

2-(3,4-Dihydro-4-oxothieno[2,3-d]pyrimidin-2-ylthio) Acetamides As a New Class of Falcipain-2 Inhibitors. 3. Design, Synthesis and Biological Evaluation

A dual target of Plasmepsin IX and X: Unveiling the atomistic superiority of a core chemical scaffold in malaria therapy

Understanding the complex formation of falstatin; an endogenous macromolecular inhibitor of falcipains

The X-ray Structure Ofplasmodium Falciparumdihydroorotate Dehydrogenase Bound to a Potent and Selectiven-Phenylbenzamide Inhibitor Reveals Novel Binding-Site Interactions

Novel Dual Inhibitors Against FP-2 and PfDHFR As Potential Antimalarial Agents: Design, Synthesis and Biological Evaluation

In Silico Study Reveals How E64 Approaches, Binds to, and Inhibits Falcipain-2 of Plasmodium falciparum that Causes Malaria in Humans

Pyrido[1,2-a]pyrimidin-4-ones As Antiplasmodial Falcipain-2 Inhibitors

Identification of potential inhibitors of casein kinase 2 alpha of Plasmodium falciparum with potent in vitro activity

High Target Homology Does Not Guarantee Inhibition: Aminothiazoles Emerge as Inhibitors of Plasmodium falciparum